Bausch & Lomb (STU:S2L) Beta: 0.9198 (As of Jun. 25, 2026)


STU:S2L Bausch & Lomb Corp STU:S2L
77 GF Score
Price €13.60
GF Value €15.84
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bausch & Lomb Beta?

Bausch & Lomb STU:S2L +2.26% 77 Beta is 0.9198 as of Jun. 25, 2026. GuruFocus rates STU:S2L with a GF Score™ of 77/100 and a GF Value™ of €15.84 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Bausch & Lomb's Beta is 0.9198.


Bausch & Lomb  (STU:S2L) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Bausch & Lomb Beta Related Terms


Bausch & Lomb Beta Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb Beta Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.22

Bausch & Lomb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.26 0.55 0.22 0.69

STU:S2L vs ISRG, BDX, MDLN: Beta Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch & Lomb Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Beta distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Beta falls into.


STU:S2L
77GF Score
Bausch & Lomb Corp STU:S2L
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch & Lomb Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.9198 mean?
Bausch & Lomb (STU:S2L) has a Beta of 0.9198 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bausch & Lomb and its competitors.
Is Bausch & Lomb's Beta too high?
Bausch & Lomb's current Beta is 0.9198. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Beta compare to ISRG and BDX?
Bausch & Lomb's Beta of 0.9198 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bausch & Lomb and its competitors. Bausch & Lomb's current Beta is 0.9198. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (STU:S2L) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.84, compared to a current price of €13.60 — trading 14.1% below its estimated fair value. The current Beta is 0.9198. Bausch & Lomb's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Bausch & Lomb (STU:S2L), the current Beta is 0.9198 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (STU:S2L) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of €13.60 is trading 14.1% below its estimated GF Value™ of €15.84. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for STU:S2L:

  • Beta: 0.9198
  • GF Value™: €15.84 vs. price of €13.60 (14.1% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the STU:S2L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bausch & Lomb Business Description

Other Exchanges BLCO:USABLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for STU:S2L

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.60
Price
€15.84
GF Value